Lenalidomid Al

Lenalidomide, the active ingredient in Lenalidomid Al, is an immunomodulatory agent presented as an oral formulation for oral use. It is used to treat certain blood cancers, specifically multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomid Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with distribution originating from the European Union market. The company ensures quality compliance with EU regulatory standards and provides reliable logistics for global procurement.

Lenalidomide is indicated for hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone marrow.

- Multiple myeloma (relapsed or refractory): improves progression‑free survival and disease control. - Myelodysplastic syndromes with del(5q) cytogenetic abnormality: reduces transfusion dependence and improves blood counts. - Multiple myeloma (maintenance therapy): helps sustain remission after initial treatment.

Lenalidomide may cause a range of adverse reactions, classified as common or serious.

Common Side Effects: - Neutropenia: reduced white blood cell count. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Nausea: upset stomach. - Rash: skin irritation.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia or leukopenia: increased infection risk. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury.

When prescribing Lenalidomid Al, clinicians should observe several safety precautions. - Pregnancy contraindication: product is teratogenic (Category X) and must not be used during pregnancy. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Renal and hepatic function: adjust use in patients with impaired kidney or liver function. - Drug hypersensitivity: discontinue if severe allergic reactions occur. - Store at room temperature (below 25°C): keep in original packaging, protect from moisture and light.

Lenalidomid Al can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure and toxicity. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inducers (e.g., rifampin): may reduce drug levels and efficacy. - Live vaccines: immunosuppression may diminish vaccine effectiveness. - NSAIDs: additive risk of thrombosis.